Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped up prior to trading on Wednesday . The stock had previously closed at $21.05, but opened at $21.8999. Chugai Pharmaceutical shares last traded at $21.0450, with a volume of 34,887 shares.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CHGCY shares. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. Finally, The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Chugai Pharmaceutical currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The stock’s 50 day simple moving average is $22.02 and its two-hundred day simple moving average is $24.99. The stock has a market capitalization of $69.00 billion, a PE ratio of 22.79 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. As a group, equities research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.